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Simple Summary: Prostate cancer treatment decisions are based on clinical stage and histological
diagnosis, including Gleason grading assessed by a pathologist, in biopsies. Prior to staging and
grading, serum or blood prostate-specific antigen (PSA) levels are measured and often trigger
diagnostic examinations. However, PSA is best suited as a marker of cancer relapse after initial
treatment. In this review, we first narratively describe the evolution of histological grading, the
current status of Gleason pattern-based diagnostics and glance into future methodology of risk
assessment by histological examination. In the second part, we systematically review the biomarkers
that have been shown, independent from clinical characteristics, to correlate with clinically relevant
end-points, i.e., occurrence of metastases, disease-specific mortality and overall survival after initial
treatment of localized prostate cancer.
Abstract: Gleason grading remains the strongest prognostic parameter in localized prostate ade-
nocarcinoma. We have here outlined the evolution and contemporary practices in pathological
evaluation of prostate tissue samples for Gleason score and Grade group. The state of more observer-
independent grading methods with the aid of artificial intelligence is also reviewed. Additionally, we
conducted a systematic review of biomarkers that hold promise in adding independent prognostic or
predictive value on top of clinical parameters, Grade group and PSA. We especially focused on hard
end points during the follow-up, i.e., occurrence of metastasis, disease-specific mortality and overall
mortality. In peripheral blood, biopsy-detected prostate cancer or in surgical specimens, we can
conclude that there are more than sixty biomarkers that have been shown to have independent prog-
nostic significance when adjusted to conventional risk assessment or grouping. Our search brought
up some known putative markers and panels, as expected. Also, the synthesis in the systematic
review indicated markers that ought to be further studied as part of prospective trials and in well
characterized patient cohorts in order to increase the resolution of the current clinico-pathological
prognostic factors.
Keywords: prostate cancer; survival; biomarker; Gleason grading; grade grouping
1. Introduction
Prostate cancer (PCa) diagnosis is based on needle biopsy histological assessment.
The current globally accepted grading system, Gleason grading has been a product of
prospective studies searching for prognostic features. The Gleason score (GS) is based on
two complementary grade patterns that relate strictly to glandular architecture of the neo-
plastic tissue. As its foundation has held through the decades, some relevant changes to the
grading criteria have been introduced during the last 15 years. The accumulating research
on the significance of different grade patterns and morphologies has been consolidated into
consensus criteria of reporting the grades and into the novel Grade grouping (GG) system,
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which simplifies the message and correlates even better with prognosis in many aspects.
As we review the evolution of Gleason grading and the most important contemporary
criteria of reporting of prostate tissue samples, we also review the current advances in
quantitative and image analysis-driven cancer grading.
Although Gleason grading is considered the most significant prognostic factor in
localized PCa, it does not inherently hold information on the biological features or genomic
changes of the cancer. As a result of Gleason grading evolution, most of the new PCa
diagnoses fall into GS 7 or GG 2/3, thereafter leaving the treating clinician with a need
for further risk stratification and prognostic assessment. As one third of the patients
experience so-called biochemical recurrence, i.e., BCR (PSA-levels increasing after initial
treatment) during follow-up, BCR is considered only as a surrogate endpoint to metastasis
or mortality later along the course of the disease. We have systematically in this report
reviewed the published literature on putative biomarkers for clinically relevant endpoints,
namely occurrence of metastases, PCa-specific death or death of any cause, in localized
PCa. Emphasis is put into independent prognostic significance of the markers, most of
which were found to be tissue biomarkers, in order to delineate their potential in aiding in
risk assessment in addition to the conventional risk parameters. Some of the markers we
found are reviewed in more detail in this Special Issue [1]. The publications on biomarkers
with the strongest independent association with the abovementioned hard end-points are
further explained in context of the source of the biomarker, whether being pre-treatment
biopsy, surgical specimen, or peripheral blood.
2. Historical Development of Prostate Cancer Grading
Histopathological diagnosis of PCa stems from the first bright light microscopy ex-
amination and description of abnormal changes by J. Adams, a surgeon who worked at
the London Hospital, in 1853 [2]. The first report concerning correlation of the histological
state and the malignant potential of the disease was published by Broders in 1925. He
invented a four-tier grading system that was based on the ratio of undifferentiated cells to
the differentiated ones [3,4].
The basis for the current PCa grading system was introduced in 1966 by Donald F.
Gleason. The system was created on the basis of a study performed in the years 1959–1964
by the Veteran’s Affairs Cooperative Research Group (VACURG), a research group set up by
the lead urologist George T. Mellinger at the Minneapolis Veteran’s Hospital. Two hundred
and seventy men were enrolled and the material used in the study was acquired from
transurethral resections, biopsies, and radical prostatectomies (RP). Instead of cytology, a
range of glandular architectural grade patterns was applied to assign a combined Gleason
score, which was a product of a statistical approach showing that two grades combined
are more accurate in outcome prediction than using only one grade pattern. The group’s
study demonstrated a correlation between the increase in cancer specific-mortality and
an increase in the histological score [5]. Gleason’s grading system was later validated by
Gleason and Mellinger to have predictive value for disease specific mortality in a study
made on 1032 patients [6]. Subsequently, several grading systems were compared in
workshops organized by the American Cancer Society, and the Gleason grading system
was recommended for broader use. Until this day Gleason score remains practically
the strongest predictor of the natural course of the disease [7] and is a principal part of
nomograms predicting the preoperative stage or post-therapy survival [8–12].
3. Contemporary Practices in Gleason Grading–ISUP Grade Groups
In almost 60, years medicine has taken a huge step forward in both clinical and patho-
logical practices. Following the accumulating new knowledge on clinical significance of
histological changes, more precise diagnostic tools (such as ultrasound-guided core biop-
sies and immunohistochemistry refining benign vs. malignant glandular arrangements),
and advancements in treatment modalities, the Gleason scale has been updated throughout
the years.
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The original Gleason system had many drawbacks; back in those days even some of the
current histological forms of PCa were not even recognized. Neither was it recommended
to report about the existence of minor high-grade components. In addition, there were no
recommendations concerning biopsy sampling and the only diagnostic tool available was
digital rectal examination. Some of the original criteria of grading, especially in the grade
patterns 1 and 2, have been shown to present non-malignant changes or very indolent
disease. Thus, currently grade patterns 1 and 2 are not recommended for biopsies at all
and grade pattern 2 very seldomly in surgical specimens [13,14].
Based on the above development, the first major changes to the Gleason grading
system were introduced by the International Society of Urological Pathology in 2005.
During that meeting, the grading system underwent major revision. Medical professionals
came to the conclusion that Gleason pattern 3 presenting large cribriform glands should
be now graded as Gleason pattern 4. The update to the “modified Gleason” leads to a big
discrepancy when analyzing data prior to 2005. However, no consensus was achieved on
poorly formed and fused cribriform glands.
Later on, during the 2014 ISUP consensus conference it was accepted that all cribriform
structures were to be graded as Gleason Pattern 4. This is due to the fact that numerous
studies demonstrated that cribriform glands were related to adverse prognosis regardless of
their morphology [15–18]. Some pathologists, however, had practiced this scheme for some
time before the consensus meeting [13]. It was also agreed that Glomeruloid structures
should be included into Gleason 4. Mucinous structures were to be graded according
to their underlying growth pattern rather than all being marked as Gleason 4. When it
comes to intraductal carcinoma of the prostate (IDCP), scientists came to a consensus that
only invasive carcinoma should be incorporated into the Gleason score. During the 2014
meeting a new five tier Grade group system was accepted to be reported together with the
Gleason score [15].
The most recent ISUP consensus meeting took place in 2019. The major changes to
the Gleason grading system concerned the minor/tertiary histological patterns, systematic
reports concerning multiple biopsy cores and MR fusion biopsies. It was agreed that
minor/tertiary Gleason 4 and 5 grades should be noted in prostatectomies and in biopsies
in cases where they constitute >5% of the volume [19].
In 2019, there was another independent working group, Genitourinary Pathology
Society (GUPS), that also published their own cancer grading manuscript. ISUP 2019 and
GUPS contain many similarities, but some key areas have major disagreements when it
comes to recommendations and conclusions. According to GUPS, IDCP should not be
included in determining the final Gleason score but it should nevertheless be reported. It
is also recommended by GUPS to perform immunohistochemistry in case of ICDP if the
Gleason score is 6 or there is a suspicion of cribriform carcinoma. According to ISUP on
the other hand, IHC is unnecessary as ICDP should be incorporated automatically in the
Gleason score. Another significant disagreement arose around minor/tertiary patterns.
According to ISUP, even high-grade components, in the presence of only two histological
types of malignant tissue, should be graded as minor when they represent <5%. According
to GUPS three different grades have to be present and if grade 5 represents >5%, it should be
accounted as a secondary pattern. According to GUPS “minor pattern” is the recommended
form with the exception of Grade groups 2 and 3 where “tertiary pattern” should be
used [20].
4. Quantitative Gleason and Artificial Intelligence
Traditional Gleason grading describes the histopathological state of the prostate in
a reasonably rigid categorical fashion which subjects it to big inter-observer variability
between growth patterns. The idea behind quantitative Gleason grading is that the cancer
grading should rather be treated as a continuum and the categorical grade patterns should
be broken down into proportional scales of different grades. According to Sauter et al. 2016
quantitative Gleason grading is less prone to interobserver bias and provides more detailed
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information than the traditional grading categories [21]. It was also shown that presence of
high-grade tertiary patterns have a stronger correlation with negative outcome rather than
the area of secondary pattern of equal grade [22].
The use of proportionate grading is becoming easier with better access to image
repositories and related data, as well as increased computational ability for complex
artificial intelligence (AI) models. Research has shown that the accuracy and consistency
of AI algorithms, when it comes to grading, are similar or even better than that of the
general pathologists [23–25]. AI could make cancer detection and grade assessment more
efficient and less prone to human error in the future. Pantanowitz et al. showed high
accuracy of image analysis in an AI-based algorithm meant to identify and quantify PCa,
recognize low-grade and high-grade tumors and also detect perineural invasion in core
needle biopsies [26]. There definitely is a new era of AI-augmented histological image
analysis trying to come up with new methods for prognostication as well.
Until now, modifications to the Gleason grade have concerned the histological ap-
pearance. With new knowledge and computational technologies available, there is room
for further development in PCa grading. Also, with advancement in machine learning
and AI technologies, new predictive algorithms could be possible to aid clinicians in their
work. We are living at the beginning of a revolution where computers can perform com-
plex cognitive tasks interactively with humans or independently. Big data combined with
computer-aided analysis can lead to recognition of complex patterns that were very time
consuming or were even never thought of before. This creates a possibility of integrating
Gleason grading with advanced genomic studies, biochemistry, multiparametric imaging
and electronic patient records to create tools for risk stratification and decision-making in a
longer time perspective [24]. Especially, when thinking about active surveillance versus
radical treatment, there is a need for more prognostic factors in order to somewhat predict
the possible progression of cancer over time [27].
There have been multiple publications describing correlation between a variety of
biomarkers and prognosis. Such methods after validation could constitute a whole new
tool for the PCa diagnostics and creation of a personalized treatment plan. In the following
chapters, we describe the current knowledge on predictive tissue biomarkers at the time
of diagnosis for clinically local PCa. We especially concentrate on the clinically relevant
end-point of disease-specific survival, overall survival and metastasis-related survival. The
independent prognostic significance of the biomarkers is weighted against the established
clinical parameters, such as Gleason grading.
5. Systematic Review of Biomarkers Related to Clinically Relevant Endpoints
In order to curate publications of prognostic or predictive (which by a strict definition
means comparing different treatment groups) biomarkers related to clinically relevant
end-points after treatment of local PCa, we conducted a systematic literature search. Please
see the PRISMA diagram (Figure 1) for an overview of the systematic review strategy.
A systematic Pubmed query was performed in October 2020 (search parameters
are provided in Appendix A) for results between 2010 and 2020. The search returned
n = 4377 results, of which 4104 remained after removing duplicates. Titles and abstracts
were downloaded for all non-duplicated papers using the R (version 4.0.1), package
easyPubMed. We then applied regular expression key-word string searches for inclusion
criteria terms regarding survival analysis with regards to study-defined “hard outcomes”
(metastasis-free survival, overall survival, disease-specific survival), or primary therapy,
which resulted in n = 1569 articles being taken forward for screening. These were screened
for inclusion criteria from the title and abstract, which resulted in n = 128 papers being
taken to full-text screening. During full text screening, we sought to determine whether
biomarkers were assessed in multivariate regression analyses against hard outcomes of
metastasis-free survival, overall survival, and disease-specific survival, which resulted in
n = 55 publications for further reporting. Please refer to Table 1 for the final summary of
systematically reviewed articles in our study.
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Analysis Info Outcome Correlation
Biopsy, IHC [28] Tollefson 2014 RP Ki-67 MFS, DSS Positive
[29] Verhoven 2013 RT + ADT Ki-67 DSS, MFS Positive
[30] Pollack 2015 RT + ADT Ki-67, MDM2, p16, Cox-2 MFS Negative/Positive
[31] Krauss 2011 RT + ADT Chromogranin A (CgA) MFS, DSS Positive
[32] Cattrini 2019 RP, RT, ADT POSTN OS, MFS * Positive
[33] Jacobs 2016 RT + ADT EZH2 MFS Negative
[34] Kammerer-Jacquet 2020 AS Ki-67 DSS Positive
RP, IHC [35] Megas 2016 RP, RT, ADT ER(α), ER(β) OS, MFS * Positive/Negative
[36] Grindstad 2018 RP ER(α), Aromatase MFS *, DSS Negative
[37] Fujimura 2012 RP, RT, ADT SXR, CYP3A4 RP and Western blot DSS Negative
[38] Quinn 2020 RP, RT, ADT p53 MFS, DSS Positive
[39] Jiao 2014 RP PPM1D OS Positive
[40] Diao 2016 RP Tra2β OS Positive









Analysis Info Outcome Correlation
[41] Mortezavi 2018 RP, ADT LC3b DSS Negative
[42] Staibano 2010 RP BAG3 MFS Positive
[43] Tradonsky 2012 RP Hey2 MFS Positive
[44] Grosset 2019 RP NF-κB p65 MFS, DSS Positive
[45] Ness 2018 RP PD-1+ stromallymphocytes MFS * Positive
[46] Fleischmann 2011 RP + ADT CD10 LN+ patients only OS Positive
[47] Nonsrijun 2015 RP MMP-11 DSS Positive
[48] Hamid 2020 RP, RT, ADT PTEN OS and MFS ** Negative
[49] Lahdensuo 2018 RP ERG, PTEN, DSS Negative
[50] Lin 2017 RP MYPT1 OS Negative
[51] Nordby 2015 RP VEGFR-2 MFS * Positive
[52] Borkowetz 2020 RP NRP2 DSS Positive
[53] Liu 2012 RP Vasculogenicmimicry (VM) OS, MFS * Positive
[54] Nordby 2018 RP, ADT, RT PDGFR-β MFS * Positive
[55] Guo 2017 RP PLAGL2 OS Positive
[56] Zhang 2016 RP GOLPH3 OS Positive
[57] Tretiakova 2017 RP Ki67 OS, DSS, MFS * Negative
[58] Haldrup 2017 RP SLC18A2 OS Negative
[59] Rynkiewicz 2015 RP, RT, ADT INPP4B MFS * Negative
[60] Genitsch 2017 RP MUC1 RP and LN Mets DSS Positive
[61] Hammarsten 2017 AS + TURP Caveolin-1 RP and TURP DSS Negative
Tissue—other [62] Nguyen 2018 RP, RT + ADT Decipher exon microarray, Bx MFS Positive
[63] Van DenEden 2018 RP Oncotype DX RNA-PCR, Bx MFS, DSS Positive
[64] Zeng 2016 RP TMPRSS2-ERG RP and Bx, FISH OS Positive
[65] Castro 2016 RP/RT + ADT BRCA1 and 2 Mutational analysis,Bx and RP DSS, MFS Positive
[66] Cooperberg 2015 RP, RT + ADT Decipher RNA hybridisation, RP DSS Positive
[67] Ross 2016 RP Decipher RNA hybridisation, RP MFS Positive
[68] Zhao 2016 RP, RT PSMB4, PSMB7, PSMD14,PSMB2, PSMD11
RNA microarray
hybridization, RP MFS Positive
[69] Zhao 2016 RP NVL, SMC4, SQLE qRT-PCR MFS, OS Negative
[70] Moen 2018 RP, RT, ADT catalytic subunit Cβ2 RNA nanostring, Bx DSS Positive
[71] Evans 2016 RP, RT, ADT 17 genes, DDR pathway GSEA, RP OS, MFS Positive
[72] Hu 2016 RP, RT, ADT AXIN2 qRT-PCR, RP MFS Negative
[73] Schmidt 2019 RP 4-miRNA ratiomodel (MiCaP) miRNA PCR, RP DSS Negative/Positive
[74] Richardsen 2020 RP miR-424-3p miRNA ISH, RP MFS * Negative
[75] Laursen 2020 RP miR-615-3p miRNA-PCR, RP DSS Positive
[76] Troyer 2015 RP PTEN FISH, RP DSS * Negative
[53] Liu 2013 RP PTEN, MYC SNP array analysis, RP DSS Negative/Positive
Blood [77] Thurner 2016 RT + ADT Plasma fibrinogen level Fibrinogen assay DSS, OS Positive
[78] Renner 2019 RT + ADT Leukocyte relativetelomere (RTL) DNA-PCR OS, DSS Positive
[79] Lévesque 2015 RP CYP1B1, COMT, andSULT2B1 (3 SNPs) SNP genotyping OS, MFS * Positive/Negative
[80] Schoenfeld 2013 RP, RT + ADT Ribunuclease-L(rs12757998) SNP genotyping DSS and MFS ** Negative
[81] Szarvas 2014 RP + TURP IMP3 ELISA DSS Positive
AS = Active surveillance, Bx = Biopsy, RP = Radical prostatectomy, RT = Radiotherapy, ADT = Androgen deprivation therapy,
IHC = Immunohistochemistry, ISH = In situ hybridization, PCR = Polymerase chain reaction, GSEA = Gene set enrichment analysis,
TURP = Transurethral resection of the prostate, DSS = Disease-specific survival, OS = Overall survival, MFS = Metastasis-free survival.
*: Outcome is a composite outcome including non-hard outcomes. **: The study did not analyze the outcomes separately.
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As most of the studies consider RP patients and less frequently radiation therapy
(RT) patients, we stratified the biomarkers based on the source of biological specimen and
method of analysis. This created groups of tissue biopsy, tissue RP, blood as sources of
biomarkers, and connected them to methods of analysis such as immunohistochemistry,
PCR, ELISA, FISH, and RNA hybridization.
In order to focus on studies of long term outcomes of primary PCa, we also excluded
any reports that analyzed patient cohorts in advanced stages or under adjuvant treatment,
including CRPC. Androgen deprivation therapy combined with RT was accepted as it is a
standard combinatorial treatment for many of the local PCas. Thus, the review included
only patients at the time of diagnosis or primary treatment having hormone naive PCa.
Additionally, during the composition of the systematic review part, we curated relevant
literature that was missed by the Pubmed search terms but met the same inclusion criteria.
These publications were then cited accordingly in each relevant section in the results.
5.1. Results
Table 1 summarizes the finding of the systematic review into distinct categories based
on the practical approach concerning the source material and the analysis method.
5.1.1. Biopsy-Based Biomarkers—Radiation Therapy and Radical Prostatectomy
At the time of diagnosis, the treatment decisions are based on cancer grade in biopsies.
The standard treatments with radical intent for localized PCa are prostatectomy and
radiation therapy. The choice of treatment depends on conventional risk-assessment
and patient-related factors, including expected life-years after the diagnosis. For more
individualized risk assessment, weighting clinically relevant cancer-related endpoints
against competing causes of death is essential. Nomograms built combining conventional
risk parameters such as PSA (including PSA-kinetics and density), clinical stage, proportion
of cancer in biopsies, and Gleason score are beyond this review, and we are concentrating
on putative biological signatures as biomarkers. First, we describe the biomarkers based on
a systematic review that have been shown in diagnostic biopsies to predict either metastasis
or death during the follow-up after radical treatment.
Certain gene panels assessed in biopsies and that have been commercialized have
shown independent significance for clinically relevant events after radical prostatectomy.
Prolaris, a 31-gene cell cycle progression panel assessed in biopsies before RP can predict
metastasis formation after the treatment [82]. Decipher, a commercially available 22-gene
RNA transcript-based algorithm is predictive of metastasis after primary treatment whether
it is RT or RP together with adjuvant androgen deprivation therapy (ADT) [62,83].
Another commercially available gene panel is Oncotype DX. A validated and commer-
cially available biopsy-based 17-gene panel relying on polymerase chain reaction assay was
tested by Van Den Eeden et al. Almost 300 men were treated with RP only and a Genomic
Prostate Score (GPS—scale 0–100) was assessed. This panel turned out to be independently
significant for MFS and DSS. The higher the score the worse the outcome. According to the
authors patients with low scores did not present with metastases during the observational
period [63].
In general, proliferation is considered low in primary PCa. However, common prolif-
eration marker Ki-67 has shown predictive value in a number of studies. As a stepwise
variable it showed independent significance for poor outcome in terms of MFS and DSS
by Tollefson et al. Ki-67 was included in their so-called Mayo model together with Per-
ineural Invasion, and Gleason Score. This biopsy-based panel was compared with the RP
outcome. As a conclusion the authors suggest that Ki-67 should be routinely assessed in
biopsies together with perineural invasion and Gleason [28]. Verhoven et al. also showed
independent significance for the same endpoints (MFS and DSS) as in the abovementioned
study with dichotomized Ki-67 using a 6.2% cut-off for a group of patients treated with
RT ± ADT [29]. The differences between RT + ADT and RT alone arms were measured
only in univariate analysis [29]. Ki-67 has also been shown to be independently significant
for poor MFS by Pollack et al. in a study of four different genes. Ki-67, MDM2 and Cox-2
Cancers 2021, 13, 628 8 of 21
correlated positively with poor outcome whereas p16 had a negative correlation. In other
words, high expression of p16 was protective since it is a tumor suppressor gene. All are
independently significant predictive factors among patients treated with RT and either
long or short term ADT. The authors suggest that they should be used together as a gene
panel. They even created a hypothetical 65-year-old patient model with fixed values of
PSA, Gleason and T scores. This patient’s characteristics showed a difference in 10-year
predicted risk when compared against favorable and unfavorable biomarker status [30].
Neuroendocrine (NE) characteristics are usually acquired during ADT, and primary
NE carcinomas are rare. Increased expression of NE biomarker Chromogranin as a contin-
uous variable was independently significant for shorter MFS and DSS in patients treated
with RT ± ADT. Krauss et al. admit that most of the patients selected for this analysis had
a Gleason score 8–10 which may have led to a selection bias of more patients receiving
ADT [31].
Periostin is a secreted extracellular matrix protein that interacts for example with
integrins and might promote cancer epithelial mesenchymal transition [84]. High Periostin
expression is an independently significant predictor of poor OS as well as a composite
outcome including radiographic progression and recurrence-free survival. The study by
Cattrini et al. was performed on patients treated with RP, RT, or ADT for locally ad-
vanced/metastatic disease [32].
TMPRSS2-ERG is one of the first fusion genes detected in solid human tumors [85]
and it is present in approximately 50% of localized PCas. A study by Zeng et al. showed
independent significance of TMPRSS2-ERG fluorescence in situ status as a prognostic
factor for poor OS in patients treated with RP. Material for the purpose of this study was
provided by both RP and biopsies [64]. ERG immunohistochemistry has been shown to
correlate strongly with the fusion-gene status but the prognostic value for MFS, DSS, or
OS in biopsies does not seem to be significant. We discuss later its role together with
tumor-suppressor PTEN in survival prediction.
Loss of tumor-suppressor Disabled homolog 2-interacting protein (DAB2IP) is an
independently significant predictor of poor MFS on the basis of pretreatment biopsy among
patients treated with RT and ADT according to Jacobs et al. They also suggest that DAB2IP
loss might explain the differences in tumor aggressiveness and radiation resistance. In the
same study the expression of EZH2 was also measured for hard endpoints but statistical
significance was not observed since almost all PCa samples expressed this biomarker. The
authors suggest that higher expression of EZH2 could be used as a screening for high-risk
patients since this biomarker was observed in poor outcome patients [33]. Another, and
one of the most studied, tumor-suppressor genes is phosphatase and tensin homolog on
chromosome 10 (PTEN) which is lost in approximate 20% of PCas. The loss of PTEN
releases PI3K pathway activated by growth factors and leads to, e.g., AKT and mTOR-
regulated cellular growth, survival and cancer cell migration. Its various roles in cancer are
beyond this review but we will focus on its prognostic role in human samples.
DNA repair-related genes have been shown to be altered and inactivated in PCa
as well. Castro et al. analyzed the relevance of BRCA1 and 2 mutations in two separate
cohorts. One was a biopsy-based RT cohort and in the second patient were treated with
RP. In both cohorts, some patients received ADT, however it was much more common in
the RT cohort. Since there was no significant statistical interaction between BRCA status
and treatment modality for either of the two endpoints, separate prognostic analyses were
not justified according to the authors. An assumption was made that BRCA affected both
cohorts similarly. Finally, BRCA carriers were proven to have worse DFS and MFS [65]. Na
et al. found similar results, in a cohort of primary PCa patients, and identified that patients
harboring a BRCA mutation had significantly poorer DSS [86].
5.1.2. RP Specimen-Based Markers
Decipher, a gene panel mentioned above, is independently significant in predicting
disease specific survival as proven by Cooperberg et al. In this study patients were mainly
treated with RP but also with or without adjuvant RT and adjuvant ADT [66]. Ross et al.
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concluded that Decipher is correlated with MFS [67]. Both of these papers concentrated on
post prostatectomy risk assessment.
Liu et al. used Affymetrix 6.0 single-nucleotide polymorphism microarrays to screen
chromosomal copy number alterations (CNAs). Among all the CNAs tested only two genes
showed independent significance in MVA. PTEN loss and MYC gain were either separately
or jointly prognostic factors of poor DSS. The main cohort consisted of patients treated with
RP only and the abovementioned results were confirmed with three other cohorts (MSKCC,
KUH, JHH) [87]. Zhao et al. used an Affymetrix GeneChip array to analyze RNA transcript
measures in four prostatectomy cohorts (including one in which patients received RT
after surgery). High expression of RNA transcripts in five genes were identified as being
prognostic. Three or more of the following proteasome genes (PSMB4, PSMB7, PSMD14,
PSMB2, and PSMD11) have to be present in order to be independently significant for poor
MFS. The authors also found that the correlation was more pronounced among younger
patients suggesting that this biomarker could be used in this specific age group and also
puts the use of proteasomal inhibitors among older groups under a question mark [68].
Zhao et al. initially tested 20 genes in patient cohorts treated with RP and in some cases
with adjuvant radiotherapy. Out of these, only the three showed independent significance
and a novel outliner gene panel was created. The outlier score from the triple gene panel
including NVL, SMC4, and SQLE was independently associated with poor MFS and OS.
The three top outlier genes were later validated [69].
Androgens are shown to have potential to regulate the expression of protein kinase
A (PKA) and its subunits in PCa cells. The PKA pathway is also linked to the androgen
receptors in PCa. Moen et al. showed that low expression of Cβ2 subunit of PKA by mRNA
analysis in PCa samples was an independently associated prognostic factor of poor DSS.
The study was divided into three different cohorts where patients were mostly treated
with RP but also with or without RT/ADT. RNA analysis of Cβ2 was dichotomized with a
cut-off value of 130 [70].
Evans et al. developed a novel patient-level gene set enrichment analysis-based path-
way profiling approach that they further applied on patients treated with RP with or with-
out adjuvant RT/ADT. The authors used Affymetrix Human Exon 1.0ST GeneChips, which
included a panel of 17 DNA damage and repair (DDR) pathway genes. Over 1000 patients
were divided into a training cohort and three validation cohorts. The DDR signature was
proven to be an independently significant prognostic factor associated with poor MFS and
OS among younger patients (<70). This biomarker could be used as a prognostic tool in
risk stratification, according to the authors. Correlations with AR and ERG expression were
also analyzed and were proven to be significant [71]. Another DDR-related work by Castro
et al., which was mentioned above, showed that not only in pre-treatment biopsies but also
in RP specimens, BRCA1 and 2 gene mutations are independently significantly prognostic
for poor DFS and MFS [65].
Gene expression analysis from RP specimens by Hu et al. showed that low AXIN2, a
protein involved in negative regulation of beta-catenin and wnt pathway, expression in
RT-PCR was proven to be independently significant for poor MFS. In this cohort, patients
were treated primarily with RP but also in some cases with adjuvant RT and neo/adjuvant
ADT. The prognostic significance of AXIN2 expression was further externally validated in
a separate cohort. The study even showed in vitro and in vivo correlation of low AXIN2
levels with increased invasiveness and tumor growth. As a conclusion, the authors suggest
that this gene might be used in creation of targeted therapy as it is strongly associated with
neoplastic growth [72].
MicroRNAs (miRNAs) are involved in various key cellular processes including pro-
liferation and differentiation. They are also diverse epigenetic regulators of malignant
transformation [88]. Schmidt et al. trained and validated a novel 4-miRNA prognostic
ratio model meant to stratify the risk of post RP patients. Six potential prognostic miRNAs
were initially identified, leading to the creation of a 4-miRNA model (MiCaP). The authors
assessed a ratio of 4 mi-RNAs (miR-10b-5p, miR-23a-3p, miR-133a, and miR-374b-5p), and
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found that that the combined MiCaP panel when analyzed in RP specimens was prognostic
of DSS. The presented data was later validated in two independent cohorts [73]. Low
miR-424-3p expression among patients treated with RP is a significant independent factor
of poor composite outcome (clinically palpable tumor or metastasis verified by radiology)
as shown by Richardsen et al. Biomarker expression was dichotomized into low vs high.
According to the authors, the abovementioned results highlight the importance of miR-424-
3p being a potential target of therapeutic treatment [74]. Another short non-coding RNA
was presented by Laursen et al. in a study based on patients treated with RP only. High
expression of miR-615-3p appeared to be a prognostic factor of poor DSS. The material was
analyzed using miRNA-PCR and the data acquired was dichotomized [75].
Elevated protein expression of estrogen receptor ER(α) and low ER(β) are both inde-
pendently significant prognostic factors of poor OS and composite outcome (local recur-
rence and distant metastasis) among patients treated with RP, according to Megas et al. [35].
In a study performed on patients treated with RP only by Grindstad et al., in addition to
the two above-mentioned biomarkers, the significance of aromatase was also analyzed.
In contrast to the results reported by Megas et al., the authors reported that higher ERα
was associated with better DSS and a composite outcome including local symptomatic
recurrence and/or findings of metastasis to bone, visceral organs, or lymph nodes. The
authors also found that higher aromatase expression was associated with better composite
outcome. The combination of these two biomarkers was independently significant for
better DSS and composite outcome. ER(β) did not show independent significance [36].
In terms of hormonal regulation markers, a combined IHC analysis of steroid and
xenobiotic receptor (SRX) and its target gene cytochrome CYP3A4 was performed by
Fujimura et al. among patients treated with RP and, in some cases with adjuvant androgen
deprivation and/or radiation therapy. Lowered expression of both of these biomarkers was
shown to be independently significant prognostic factors of worse DSS. The authors suggest
that the fact, that SRXr regulates the cytochrome-mediated inactivation of testosterone,
could be used as a target for therapy in PCa [37].
Cell cycle regulator p53 nuclear protein expression reflects mutation in TP53 gene and
has recently shown to relate with poor MFS and DSS independently among patients treated
primarily with RP ± adjuvant RT/ADT. Quinn et al. [38]. A second gene that is directly
associated with cell cycle regulation is protein phosphatase magnesium-dependent 1 delta
(PPM1D), which has been shown to inhibit p53 function during oncogenesis. According
to Jiao et al., higher expression of this biomarker among patients treated with RP is
significantly correlated with poor OS [39].
Transformer 2β (Tra2β), a splicing regulator-related protein was studied by Diao et al.
with IHC in RP cohort of 160 patients. Tra2β expression was dichotomized into high and
low expression groups. The former one was independently associated with poor OS. The
authors suggest that Tra2β could be used as a target of novel therapy [40].
Microtubule-associated protein 1 light chain 3B (LC3b), a component of autophago-
some formation, was analyzed by Mortezavi et al. in patients treated with RP ± neoadju-
vant ADT. This biomarker was shown to be independently associated with better DSS [41].
BAG family molecular chaperone regulator 3 (BAG3), on the other hand, is a co-chaperone
protein related to autophagy. Its intra-cytoplasmic delocalization is a specific feature of neo-
plastic transformation. This feature correlated with poor MFS among patients treated with
RP only, according to Staibano et al. According to the authors, this pathway could play a key
role in overcoming chemoresistance of cancer cells [42]. Positivity for Hairy/enhancer-of-
split related with YRPW motif protein 2 (Hey-2), a transcription factor, predicted increased
risk of distant metastasis by 5.6-fold compared to negative staining among patients treated
with RP only, according to Tradonsky et al. [43].
A multi-institutional study showed that elevated nuclear frequency of p65 (a NF-
κB subunit), as measured by IHC, is an independently significant prognostic factor of
development of bone metastasis and PCa-related death after RP [44]. Different subunits of
NF-κB function with various mechanisms regulating tumor initiation and growth, one of
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which is immunological environment regulation. Programmed cell death protein (PD-1) is
a T cell suppressive immune checkpoint molecule that has been shown to have a role in
many cancers. High density of PD-1 expressing intratumoral stromal lymphocytes was
shown to predict quicker local recurrence and distant metastasis among patients treated
with RP only in a study by Ness et al. [45]. Although therapies targeting PD-1 and PD-L1
have not been successful in PCa, more detailed prognostic information might lead future
clinical trials in selected patients.
High Neprilysin (or CD10) expression in local lymph node metastasis is predictive
of poor OS among patients treated with RP ± ADT according to Fleischmann et al. [46].
This might be related to the function of CD10 as a modulator of tumor microenvironment
during carcinogenesis. Another extra-cellular matrix modifying enzyme as biomarker was
presented by Nonsrijun et al. Overexpression of matrix metalloproteinase 11 (MMP-11) in
RP specimen showed independent significance as a prognostic factor of poor DSS [47].
Among patients treated primarily with RP but in some cases with adjuvant RT and
ADT, loss of PTEN expression is an independently significant prognostic factor of poor
OS and MFS, according to Hamid et al. The authors studied PTEN with quantitative
fluorescence IHC as continuous and dichotomized variable [48]. Lahdensuo et al. showed
similar results; however, here, ERG negativity paired with PTEN loss was a predictive
factor of poor DSS. Dichotomized IHC expressions of biomarkers were measured in patients
treated with RP only [49]. In a separate study of ERG status and obesity, the authors found
that increased BMI and waist circumference, particularly in ERG positive patients, was
significantly associated with poor survival [89]. Troyer et al., also studied PTEN status,
as assessed by FISH, in RP specimens. The authors found that PTEN loss in RP was
associated with poor composite outcome including DSS, MFS, clinical recurrence and
salvage treatment. According to the authors, the FISH method is very promising as it
requires less specimen material and could be applied in diagnostic biopsies [76].
Myosin phosphatase target subunit 1 (MYPT1) is inhibited by miR-30d in PCa, in a pro-
angiogenic and tumorigenic pathway. Low immunoreactivity score of MYPT1 correlates
with poor OS in RP patients according to a study by Lin et al. [50]. Nordby et al. studied
another pathway that could be a target of novel anti-angiogenic treatments in the future. In
their study, VEGFR-2 expression was associated with poor composite outcome including
local recurrence and distant metastasis among patients treated with RP without any form
of adjuvant therapy [51]. Neuropilin-2 (NRP2) is a transmembrane protein that acts as a
coreceptor of VEGF and promotes tumorigenesis possibly through mTORC2 as well [52,90].
Elevated expression of NRP2 protein (dichotomized values) is an independently significant
prognostic factor of shorter DSS among patients treated with RP, according to Borkowetz
et al. Stratification by risk factors made the prognostic value more pronounced with high-
risk PCa [52]. Another study that researched the role of angiogenesis in PCa was published
by Liu et al. Here, the presence of vasculogenic mimicry was also related to adverse OS
and a composite outcome consisting of local recurrence and distant metastasis [53].
Platelet derived growth factors (PDGFs) and their receptors (PDGFRs) are known to
be significant regulators of mesenchymal cells in different types of cancers. Nordby et al.
showed that patients treated with RP, and in some cases with postoperative ADT or RT,
had more frequently local recurrence and distant metastasis in case of high expressions
of PDGFR-β [54]. In this study, the IHC scoring was dichotomized into low and high
expressions. The function of Pleomorphic adenoma gene like-2 (PLAGL2) is not precisely
known. Research has shown however that it is a transcription factor related to tumorigene-
sis. According to Guo et al. (PLAGL2) overexpression is associated with poor OS among
patients treated with RP only [55].
Golgi phosphoprotein 3 (GOLPH3) is an oncogene that has been shown to be in-
volved with tumorigenesis in PCa and other neoplasms, and regulates (along with other
trans-Golgi matrix family proteins) rapamycin signaling [91]. According to Zhang et al.,
GOLPH3 positivity is correlated with reduced OS in patients treated with RP only. Data
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was dichotomized for this MVA but authors suggest that a numeric intensity score could
be used for measurement of the aggressiveness [56].
Tretiakova et al. performed a multi-institutional study of Ki-67 expression in 1004
prostatectomy specimens. The authors found that high Ki-67 proliferation index (measured
as a continuous variable) is a prognostic factor of poor OS, DSS, and MFS (as part of a
composite outcome additionally measuring clinical recurrence, treatment with salvage
therapy, and prostate-cancer specific mortality). They suggest that Ki-67 has potential
to be measured during routine biopsies for patients during AS [57]. On the other hand,
Pascale et al. analyzed the statistical significance of Ki-67, neuron specific enolase (NSE),
chromogranin A (ChrA), and synaptophysin (Syp) among patients treated with RP and
transurethral resection of the prostate (TURP). Regardless of the treatment, only Ki-67 was
an independently significant prognostic factor of poor OS [92].
The solute carrier family 18 member 2 (SLC18A2) is responsible for encoding genes
related to transmembrane vesicular transportation. Loss of this gene is associated with
poor OS, according to Haldrup et al. The authors suggest that the survival analysis should
be repeated with a longer follow-up time [58].
Phosphoinositide 3-kinase (PI3K)/Akt pathway is usually activated by PTEN loss.
Recent studies have however shown that loss of INPP4B has similar effects [93]. Rynkiwicz
et al. performed a cohort study on patients treated primarily with RP but in some cases also
with adjuvant RT or ADT. INPP4B loss was correlated with more frequent local recurrence
and distant metastasis [59].
High MUC1 expression in lymph node metastasis is independently significant for
unfavourable outcome in terms of DSS, according to Genitsch et al. in a study on patients
treated with RP only [60]. Interestingly, it has been previously shown that MUC1 down-
regulates the androgen receptor at the transcriptional level in cell lines [94], which may
indicate that MUC1 could be amenable for targeted therapy.
5.1.3. Peripheral Blood Markers
Increased plasma fibrinogen level is a significant independent predictor of poor DSS
and OS in patients treated with RT (±adjuvant or neoadjuvant hormonal therapy), although
the clinical parameters were stratified into binomial low and high-risk categories in the
report by Thurner et al. [77].
Leukocyte relative telomere (RTL) length shows independent significant correlation
with worse DSS and OS in patients treated with RT (±adjuvant or neoadjuvant hormonal
therapy) in a report by Renner et al. [78]. Patients were stratified into low-, intermediate-,
and high-risk groups according to the NCCN guidelines.
Steroidogenic germline polymorphism of certain SNPs (CYP1B1 (rs1800440), COMT
(rs16982844), and SULT2B1 (rs12460535, rs2665582, rs10426628)) was shown to be inde-
pendently significant for negative outcome in OS and a composite outcome (including
resistance to androgen-deprivation therapy, metastasis, and/or death) by Lévesque et al.
in a cohort of RP patients. Patients were stratified according to risk into four prognostic
subgroups. However, out of the tested genes, SULT2B1 rs2665582 and rs10426628 are
protective. The study suggested that combination of these markers, rather than each SNP
individually, should be used for better outcome prediction Adding a previously discovered
HSD17B2 (rs4243229, rs1364287, rs2955162, rs1119933) to the new biomarkers compared
in MVA creates a remarkable 8 gene panel [79]. Single nucleotide polymorphism in Ri-
bonuclease L (RNASEL) was studied in terms of outcome correlations by Schoenfeld et al.
A prospective study of patients treated with either RT or RP was performed, presence of
rs12757998 gene allele has shown independent significance in the case of the RP cohort.
In the multivariate analysis the rs12757998 variant allele was associated with a better
composite outcome including both DSS and MFS. Additionally, men homozygous for the
abovementioned allele variant were associated with a significantly reduced hazard for the
composite outcome when RT was combined with ADT [80].
Oncofetal protein insulin-like growth factor 2 (IGF2) messenger RNA-binding pro-
tein 3 (IMP3) was studied among patients treated with RP or palliative TURP by Szarvas
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et al. High IMP3 serum levels (as a continuous variable) have been shown to be an in-
dependent risk factor of DSS in both pre and postoperative models [81]. Szarvas et al.
also suggested that in addition to being a biomarker for PCa, IMP3 has potential as an
actionable immunization target
5.1.4. Active Surveillance
Active surveillance (AS) is a standard of care option for primary treatment of low to
even some intermediate risk PCa [95], and prognostic biomarkers of AS outcomes is an
area of active research [96]. Given that the aim of this review was to profile prognostic
biomarkers of primary PCa, we included AS studies in our initial screen. We did not
identify any reports from AS studies with hard outcomes in our systematic literature
search. This is not entirely unexpected, given that AS has only become a viable treatment
option within the past 10–15 years, and most studies assessing outcomes of AS analyze
easily attainable, short-term surrogate outcomes such as grade elevation in subsequent
biopsies or change to active treatment. Our search terms did not contain watchful waiting
(WW) or deferred treatment, which can include higher-risk primary PCa patients, whose
risk-profiles differ from those undergoing contemporary AS. Despite this, we identified
two relevant studies reporting associations of biomarkers assessed in prostate biopsies and
TURP specimens, and hard outcomes.
Hammarsten et al. reported that high stromal Caveolin-1, a scaffold protein involved,
for example, in signal transduction and interacting with integrins, RNA expression is asso-
ciated with favorable disease-specific survival in men under WW [61]. Kammerer-Jacquet
et al., reported results that a linear increase in prostate biopsy Ki-67 protein expression, as
detected by IHC, predicts elevated risk of disease-specific mortality, especially in GG1&2
PCas [34]. Despite inherent difficulty in interpreting these results in light of the current
standard of care, these results suggest a biological correlation of these markers with out-
come that is independent of grade (and arguably treatment). The findings from Ki-67
protein expression are in line with previously discussed results [28–30,57], that consistently
report a positive association between increased expression and poorer outcome. Indeed,
Hammarsten et al. further went on to report a similar association between Ki-67 and
poor outcome in the same WW cohort, however, they did not analyze the prognostic
value of Ki-67 with other clinical variables in a multivariable model [97]. Similarly, other
recent reports assessing Ki-67 expression status in prostate biopsies have also reported
independent association with DSS [98,99]. Reports from other WW studies have reported
an independent association of biomarkers and WW outcomes [100,101].
A number of commercial gene panels have been proposed for use in prognostication
of AS. Prolaris has been shown to be prognostic of PCa outcomes in prostate needle
biopsies [102]. Other commercially available gene panels such as Decipher [103,104] and
Oncotype Dx [105] have also been assessed in AS cohorts. However, these studies focused
on associating biomarker status with AS inclusion criteria, or short term AS outcomes
such as grade progression as subsequent biopsy, or adverse findings in pathology in RP
specimens. Further work will need to be done to assess these biomarkers identified in
this section in the context of other currently available commercial gene panels, modern
clinical standards of care such as in mpMRI targeted biopsies, and long term follow up in
AS cohorts.
6. Discussion
The aim of our systematic review was to find putative prognostic biomarkers with
strict criteria for the follow-up end points, i.e., metastasis formation, PCa-specific death
and death from any cause. Studies with BCR only during the follow-up were categorically
excluded. Another important criterion for biomarker inclusion in our review was indepen-
dent prognostic value when adjusted for the clinical conventional risk-defining parameters.
Only in this way can one expect to find markers with potential to fill the unmet need for
higher-resolution risk stratification and personalized approaches.
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The biomarker review revealed that there indeed are significant findings on markers
that relate to clinically relevant follow-up events and are independent of clinical charac-
teristics. At the same time, it revealed the heterogeneity in methodology and reporting of
these studies. Markers are very often adjusted to clinical variables or categorized in a way
that would not necessarily be applicable in clinical practice but serves the purpose of an
individual study and the cohort selected. Many of the markers are semiquantitative which
creates a problem of reproducibility. Studies mainly lack validation cohorts or the findings
have not been reproducible in another cohort later. However, some of the markers may be
considered at least partially useful or promising, although the consensus recommendations
have found them to be not clinically applicable [106–108].
There are several reasons for non-existing clinical predictive markers. Firstly, PCa is a
heterogeneous disease and some of the issues finding new stratifying predictive markers
may simply relate to, e.g., sampling the relevant lesions and detecting signals correctly in
the blood. Strategies using targeted biopsies and well-designed RP TMAs that mimic the
biopsy situation may offer solutions for this. Secondly, methodologies vary considerably
and only a small number of markers have been validated with methods that are consistent
in samples across different laboratories. In the end, a lack of prospective studies comparing
different treatment modalities that would include biomarker testing stems from the com-
plexity of designing such a study. Complexities are in patient cohort selection (same stage,
standardized treatment modalities) and in required long intervals between initial treatment
and clinically relevant endpoints. Additionally, solely a biomarker study would not per-
haps attract enough funding if not coupled with hypotheses of finding druggable targets or
theranostic molecules. In search of aids for decision-making and individualized prediction,
more standardized approaches and larger prospective multicenter studies are warranted.
One approach that our systematic search did not conceptually include is whether a
biomarker has additional (although correlative) value in prediction beyond what the clini-
copathological parameters inform us. Such statistics include ROC-AUC (receiver operating
characteristics—area under curve) analysis by which single parameters or combinations
of characteristics can be compared for any addition in predictive significance. This was
not the topic of our current review per se but to mention there are e.g., gene expression
panel-based and MRI-based studies showing improved predictions on top of clinical pa-
rameters for metastatic and lethal disease [109–113]. The future of PCa prognostic work-up
is built on multimodal approach, i.e., traditional histology (aided with image analysis
and AI solutions), biomarkers, clinical data, and imaging. Although being subjective,
Gleason grading has remained the prognostic method with most impact on treatment
choices. The divided views on certain approaches in reporting are in the end something
that is less important and emphasis should be put into lessening the variation in grade
pattern assessment. This all requires local pathology meetings and being able to consult a
colleague with a low threshold. Equally important to interobserver discussions is cross-talk
with clinicians. There should be local agreement about the reporting of pathology findings
as systematically as possible and communication about the pathologists’ approach as it
comes to ISUP or GUPS recommendations. Overall, systematic reporting of cancer extent
in biopsies facilitates more unified morphology across observers as pathologists need to
give more thought to subgrading and proportions of different Gleason patterns. In the
systematic approach and in decreasing inter-observer variation, AI will guide subpathology
reporting and facilitate unified global recommendations as knowledge accumulates. In the
near future, AI may enable the implementation of quantitative Gleason scoring through
continuous readouts, providing increased clinicopathological information as compared to
traditional stepwise grading.
7. Conclusions
Histological grading of PCa remains the gold standard in risk stratification but is
revised with quantitative approaches and image analysis algorithms. Latest research has
shown that current image based analysis performs as well as visual human Gleason grading
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in diagnostic workup. There continues to exist an unmet need for biomarkers to further
define the prognosis and aid in treatment selection of a localized PCa. Putative biomarkers
have been identified but need to be further studied in standardized fashion, most probably
complemented with other modalities such as medical imaging.
When it comes to multimodal diagnostic assessment, combining clinical data, histol-
ogy and imaging is already a recommended approach. In the future, the use of AI and
image analysis could provide more personalized approaches to treatment decision-making.
e.g., patient’s comorbidities, expected life years and calculated benefit from a particular
treatment choice could be amended with biomarker (histology, genomics, or radiomics)
based risk-assessment (See Figure 2).




Figure 2. Future prospect of a multimodal diagnostic work-up and treatment decision-making. 1: 
Prostate-specific antigen (PSA) is unspecific at the diagnostic phase and should be taken only as 
part of an informed risk assessment or based on recommendations for personalized screening. 2: 
Current evidence does not support any biomarkers. Further research is needed to implement 
biomarkers to clinical practice (as discussed in text). 
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as part of an informed risk assessment or based on recommendations for personalized screening.
2: Current evidence does not support any biomarkers. Further research is needed to implement
biomarkers to clinical practice (as discussed in text).
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Appendix A
Search Terms Used in PUBMED
(Prognosis[MeSH Terms] AND Prostatic Neoplasms/mortality[Mesh] AND biomark-
ers, tumor[MeSH Terms]) OR (Prostate[Mesh] AND Neoplasms[Mesh] AND Biomark-
ers[Mesh] AND Prognosis[Mesh] AND Tissues[Mesh]).
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